|
Re: The Pfizer connection...
|
5
|
Resverlogix Corp.
|
Nov 30, 2018 10:06PM
|
|
Re: Remembering Relypsa
|
6
|
Resverlogix Corp.
|
Nov 30, 2018 02:34AM
|
|
Re: Resverlogix Announces Publication on Apabetalone in Atherosclerosis Journal
|
3
|
Resverlogix Corp.
|
Nov 28, 2018 09:42AM
|
|
Re: What is Mr. Market saying about RVX?
|
4
|
Resverlogix Corp.
|
Nov 26, 2018 12:34PM
|
|
Re: What is Mr. Market saying about RVX?
|
5
|
Resverlogix Corp.
|
Nov 26, 2018 11:47AM
|
|
Re: What is Mr. Market saying about RVX?
|
6
|
Resverlogix Corp.
|
Nov 26, 2018 11:39AM
|
|
Re: What is Mr. Market saying about RVX?
|
3
|
Resverlogix Corp.
|
Nov 25, 2018 07:47PM
|
|
Losing exclusivity on Aberatirone may not be all that bad for JNJ or ZEL
|
3
|
Zenith Epigenetics
|
Nov 22, 2018 01:11PM
|
|
Re: Apabetalone downregulates factors and pathways associated with vascular calcification
|
2
|
Resverlogix Corp.
|
Nov 21, 2018 11:44AM
|
|
Re: Apabetalone downregulates factors and pathways associated with vascular calcification
|
2
|
Resverlogix Corp.
|
Nov 21, 2018 03:58AM
|
|
Re: Slight increase in short interest up to November 15th +15,066 shares
|
2
|
Resverlogix Corp.
|
Nov 21, 2018 03:47AM
|
|
Re: Primary endpoint: Time vs Absolute Numbers
|
4
|
Resverlogix Corp.
|
Nov 19, 2018 01:39PM
|
|
Re: Possible Zenith deal,..
|
5
|
Resverlogix Corp.
|
Nov 17, 2018 03:00PM
|
|
Re: Why such little intrest, so close to the finis
|
8
|
Resverlogix Corp.
|
Nov 16, 2018 11:50PM
|
|
Re: NEJM Editorial on REDUCE-IT
|
2
|
Resverlogix Corp.
|
Nov 16, 2018 04:18PM
|
|
Re: Amarin CEO interview - New class action lawsuit
|
3
|
Resverlogix Corp.
|
Nov 14, 2018 07:55PM
|
|
Re: AHA 2018 Resverlogix Poster #2
|
3
|
Resverlogix Corp.
|
Nov 13, 2018 12:24PM
|
|
Re: AHA 2018 Resverlogix Poster #2
|
2
|
Resverlogix Corp.
|
Nov 13, 2018 03:23AM
|
|
Re: ... unfinished business
|
5
|
Zenith Epigenetics
|
Nov 02, 2018 03:03AM
|
|
Re: The scariest thing for a clinical trial......
|
2
|
Resverlogix Corp.
|
Oct 31, 2018 08:48PM
|
